

MAR 28 2002



K020663 (P.1 of 2)

AMERICAN MEDICAL SYSTEMS

510(k) SUMMARY

Submitter's Name: American Medical Systems, Inc.

Address: 10700 Bren Road West
Minnetonka, MN 55343

Tel: 952-930-6120

Fax: 952-930-6496

Contact Person: Mark McIntyre

Date of Summary Preparation: February 28, 2002

Device Common Name: Surgical Mesh, Sling, Urethral Sling

Device Trade Name: SPARC™ Sling System

Device Classification Name: Surgical Mesh, polymeric

Predicate Device: SPARC™ Sling System – K011251, K013355

Device Description

The SPARC™ Sling System is a sterile, single use procedure kit consisting of:

- Two stainless steel, curved, 22-cm long, needle passers (also called insertion tools).
- One piece of AMS Polypropylene sling mesh with attached dilating connectors. The AMS Polypropylene sling mesh is constructed of polypropylene monofilament that is precut to 1.0 cm width x 50cm length. A fixed blue polypropylene anchoring suture runs through the middle of the sling mesh. Two plastic sheaths that overlap in the center of the sling mesh, cover the sling mesh and protect it during placement.

Dilating connectors are attached to either end of the plastic sheaths. The dilating connectors are used to attach to the vaginal ends of the SPARC™ needle passers during the procedure to facilitate sling placement.

- Two blue colored plastic cystoscopy aids are included in the kit in order to facilitate cystoscopic viewing of the bladder. The use of these cystoscopy aids is optional. The proposed device that is the subject of this 510k will not include the cystoscopy aids.



K020665 (K. 2 of 2)

AMERICAN MEDICAL SYSTEMS

Indications for Use

The indication for use for the SPARC™ Sling System is not changing. It continues to read as follows:

"The SPARC™ Sling System is intended for the placement of a pubourethral sling for the treatment of female stress urinary incontinence (SUI) resulting from urethral hypermobility and/or intrinsic sphincter deficiency."

Comparison to Predicate Device

1. The fundamental scientific technology of the device will not change with the proposed alternative configuration of the device. The device that was the subject of K013355 will continue to be marketed. The proposed alternate configuration will be a second product offering in this family of products. The needle passer handle will be modified to be permanently attached and more ergonomic. Additionally, texture will be added to the needle passer to make it easier to grip during the procedure. The packaging for the product will be changed from a double Tyvek pouch to a double tray system consisting of PETG trays and Tyvek lids. The proposed device package will not contain the cystoscopy aids. The sling mesh width has been increased from 1.0 cm to 1.1 cm.

Supporting Information

A risk analysis of the proposed modification and bench test data reported in this 510(k) application substantiate equivalence to the predicate and did not raise any new questions of safety or effectiveness.

Conclusion

The proposed modification is equivalent to the predicate with respect to intended use, technological characteristics, and performance.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

Mr. Mark McIntyre
Director, Regulatory Affairs
American Medical Systems, Inc.
10700 Bren Road West
MINNETONKA MN 55343

SEP 28 2012

Re: K020663
Trade/Device Name: SPARC™ Sling System
Regulation Number: 21 CFR 878.3300
Regulation Name: Surgical mesh
Regulatory Class: II
Product Code: OTN
Dated: February 28, 2002
Received: March 1, 2002

Dear Mr. McIntyre:

This letter corrects our substantially equivalent letter of March 28, 2002.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Benjamin R. Fisher". The signature is fluid and cursive, with the first name "Benjamin" being the most prominent.

Benjamin R. Fisher, Ph.D.

Director

Division of Reproductive, Gastro-Renal,
and Urological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE ENCLOSURE

510(k) Number:

K020663

Device Name:

SPARC™ Sling System

Indications for Use:

The SPARC™ Sling System is intended for the placement of a pubourethral sling for the treatment of female stress urinary incontinence (SUI) resulting from urethral hypermobility and/or intrinsic sphincter deficiency.

Thomas C. Provost
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K020663

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE
IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-off)
Division of General and Restorative Devices

510(k) Number _____

Prescription Use X
(Per 21 CFR801.109)

OR

Over the Counter Use _____